Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 8,090,000 shares, a growth of 10.7% from the December 15th total of 7,310,000 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 8.0 days.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded up $1.02 during trading on Monday, reaching $23.78. The company had a trading volume of 854,667 shares, compared to its average volume of 852,336. The firm’s fifty day moving average is $25.80 and its 200 day moving average is $31.84. The firm has a market capitalization of $1.58 billion, a PE ratio of -9.25 and a beta of 1.62. Celldex Therapeutics has a twelve month low of $22.17 and a twelve month high of $53.18.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Novo Holdings A S boosted its stake in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after buying an additional 654,194 shares in the last quarter. BNP Paribas Financial Markets grew its position in Celldex Therapeutics by 293.2% in the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 21,013 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Celldex Therapeutics by 47.5% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock worth $31,294,000 after acquiring an additional 272,389 shares in the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Thursday, January 2nd. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Finally, The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.